Assisted Hatching in Frozen Blastocysts

June 6, 2019 updated by: Hadas Ganer Herman, Wolfson Medical Center

The Effect of Assisted Hatching on Implantation Rate in Frozen Blastocyst Transfer - a Prospective Randomized Controlled Study

The current study aims to assess the effect of assisted hatching on the implantation rate of frozen blastocytes.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The Zona Pellucida protects the ovum from the penetration of multiple sperm, and from mechanical and physiological damage until the fertilized ovum reaches the uterus. Subsequently, spontaneous hatching occurs, and enables the embryo to attach to the endometrium. The technique of assisted hatching was originally investigated as a means to improve implantation in cases of zona hardening, and is commonly performed in 3-day embryos. In the current study, the investigators aim to investigate the effect of assisted hatching on 5-day frozen embryos.

Study Type

Interventional

Enrollment (Anticipated)

84

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • H̱olon, Israel
        • Recruiting
        • Edith Wolfson Medical Center
        • Contact:
          • Hadas Ganer Herman, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 39 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • In-vitro fertilization patients at the investigators' institution, intended to undergo a transfer of a frozen five-day embryo (blastocyte)
  • 18 to 39 years old
  • First to third treatment cycle
  • Patient has previously had a maximum of four embryos transferred.

Exclusion Criteria:

  • Over 40 years old
  • Congenital or acquired uterine malformations
  • Hydrosalpinx
  • Chronic autoimmune diseases
  • Embryo intended to be undergo preimplantation genetic diagnosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Assisted hatching
Five-day frozen embryos will undergo assisted hatching prior to embryo transfer
Controlled hatching of the zona pellucida in the laboratory prior to embryo transfer
NO_INTERVENTION: Control
Five-day frozen embryos will not undergo any additional procedures prior to embryo transfer

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implantation rate
Time Frame: Five to six weeks following embryo transfer
Number of gestational sacs demonstrated on ultrasound divided by the number of embryos transferred (expressed as percentage)
Five to six weeks following embryo transfer

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Chemical pregnancy
Time Frame: Five to six weeks following embryo transfer
Increase and subsequent decrease in beta HCG levels with no evidence of gestational sac on ultrasound
Five to six weeks following embryo transfer
Early spontaneous abortion
Time Frame: Up to 15 weeks from embryo transfer
Spontaneous abortion of pregnancy during the first trimester of pregnancy
Up to 15 weeks from embryo transfer

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 1, 2019

Primary Completion (ANTICIPATED)

March 1, 2020

Study Completion (ANTICIPATED)

March 1, 2020

Study Registration Dates

First Submitted

February 6, 2019

First Submitted That Met QC Criteria

February 6, 2019

First Posted (ACTUAL)

February 7, 2019

Study Record Updates

Last Update Posted (ACTUAL)

June 11, 2019

Last Update Submitted That Met QC Criteria

June 6, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 0020-19-WOMC

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ART

Clinical Trials on Assisted hatching

3
Subscribe